Mu-Gene

MuGene is a South Korean biotechnology company specializing in the development of advanced gene therapy delivery systems. The company's core technology is the Mu-LNP (Mu-Lipid Nanoparticle) platform, which is designed to deliver nucleic acid therapeutics like siRNA and mRNA specifically to target tissues, particularly the liver. MuGene's pipeline focuses on treating high-unmet-need conditions such as liver cirrhosis, non-alcoholic steatohepatitis (NASH), and various solid tumors. By leveraging its proprietary delivery platform, the company aims to overcome the traditional limitations of gene therapy, such as toxicity and off-target effects.